Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a JAK inhibitor tame the immune attack in NMOSD?

NCT ID NCT05792462

Disease control Sponsor: Tianjin Medical University General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This early-phase trial tests whether baricitinib, an oral drug that blocks certain immune signals, can reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare autoimmune condition where the immune system attacks the optic nerves and spinal cord, causing vision loss and weakness. The study will give participants 4 mg of baricitinib daily for up to 96 weeks, tracking relapse frequency and changes in disability. The goal is to see if this approach is safe and may help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
baricitinib
What this could lead to
If effective, baricitinib could offer a new oral treatment option to reduce relapses and slow disability in people with NMOSD.
What could go wrong
This is an early-phase trial with only 11 participants, so results may not apply broadly. Baricitinib may also have side effects, and its benefit in NMOSD is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

11 people

The number who actually took part.

Started

Apr 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female patients ≥ 18 years old; 2. Diagnosis of NMO or NMO spectrum disorder according to the 2015 International Panel for Neuromyelitis Optica Diagnosis criteria; 3. Clinical evidence of either at least one relapse requiring rescue therapy (intravenous corticosteroids, intravenous immunoglobulin, plasma exchange or a combination of these therapies) in the year before screening or at least two relapses requiring rescue therapy in the 2 years before screening; 4. Expanded disability status scale (EDSS) score ≤ 6.0; 5. Patients were seropositive for AQP4-IgG; 6. Able and willing to give written informed consent and comply with the requirements of the study protocol. Exclusion Criteria: 1. Current evidence or known history of clinically significant infection (Herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, Hepatitis viruses, Syphilis, etc); 2. Participation in another interventional study within the last 3 months; 3. Tumor disease currently or within the last 5 years; 4. Pregnancy, breastfeeding, or child-bearing potential during the course of the study; 5. Patients with clinically relevant heart, liver, kidney or bone marrow dysfunction; 6. History of venous thromboembolism (VTE), or are considered at high risk for VTE by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nmo spectrum disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuromyelitis optica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nmo spectrum disorder

Contacts and locations

Locations

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, 300052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.